These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34748527)

  • 1. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.
    Cai L; Zhang JZ; Zheng M; Zhang SF; Patekar M
    Chin Med J (Engl); 2021 Sep; 134(21):2629-2631. PubMed ID: 34748527
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of secukinumab in psoriasis treatment.
    Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
    Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan.
    Fujita H; Ohtsuki M; Morita A; Nagao R; Seko N; Matsumoto K; Tani Y; Terui T
    J Dermatol; 2021 Feb; 48(2):175-183. PubMed ID: 33099791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
    Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB
    Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
    Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
    Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Elewski BE; Baddley JW; Deodhar AA; Magrey M; Rich PA; Soriano ER; Soung J; Bao W; Keininger D; Marfo K; Patekar M; Sharma A; Shete A; Lebwohl MG
    JAMA Dermatol; 2021 Jan; 157(1):43-51. PubMed ID: 33001147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis.
    Bongiorno MR; Pistone G; Doukaki S; Aricò M
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S15-20. PubMed ID: 18837728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis.
    Yan K; Zhang Y; Han L; Huang Q; Zhang Z; Fang X; Zheng Z; Yawalkar N; Chang Y; Zhang Q; Jin L; Qian D; Li X; Wu M; Xu Q; Zhang X; Xu J
    JAMA Dermatol; 2019 Mar; 155(3):327-334. PubMed ID: 30698628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.
    Lu J; Tang S; Yu N; Yi X; Li Y
    J Int Med Res; 2020 Nov; 48(11):300060520969494. PubMed ID: 33161790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of secukinumab in psoriasis and psoriatic arthritis: A retrospective multicentre study.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Galán-Gutierrez M; Martinez-Pilar L
    Med Clin (Barc); 2020 May; 154(9):370-371. PubMed ID: 30717997
    [No Abstract]   [Full Text] [Related]  

  • 13. Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature.
    Hsieh CY; Tsai TF
    Lupus; 2022 Jun; 31(7):891-894. PubMed ID: 35438595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ustekinumab for psoriatic arthritis.
    Cuchacovich RS; Espinoza LR
    Lancet; 2009 Feb; 373(9664):605-6. PubMed ID: 19217153
    [No Abstract]   [Full Text] [Related]  

  • 15. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
    Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
    Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
    Reich K; Warren RB; Coates LC; Di Comite G
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab retreatment associated psoriasis flare with pustules.
    El-Komy M; Amer M; Mostafa A; ElKalioby M
    J Dermatolog Treat; 2022 Mar; 33(2):1107-1110. PubMed ID: 32538223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
    McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
    Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.
    Kolbinger F; Di Padova F; Deodhar A; Hawkes JE; Huppertz C; Kuiper T; McInnes IB; Ritchlin CT; Rosmarin D; Schett G; Carballido JM; Häusermann P; Calonder C; Vogel B; Rondeau JM; Bruin G
    Pharmacol Ther; 2022 Jan; 229():107925. PubMed ID: 34171337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.